查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1447720

HER2+ 胃癌市場評估：按治療類型、階段、最終用戶和地區劃分的機會和預測（2017-2031 年）

HER2+ Gastric Cancer Market Assessment, By Therapy Type, By Stage, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 232 Pages | 商品交期: 3-5個工作天內

價格

全球 HER2+ 胃癌市場規模將從 2023 年的 13.045 億美元增長到 2031 年的 17.059 億美元，在 2024 年至 2031 年的預測期內複合年增長率為 3.37%。

由於胃癌病例數增加，HER2+胃癌市場正在持續成長。 所有年齡層的病例都有所增加。 技術進步、研發投資增加以及政府措施也正在推動市場發展。 胃癌的盛行率在全球範圍內迅速增加，幾乎佔不同類型癌症的 5%。 市場正在經歷解決方案的技術進步，這些解決方案可以在更短的時間內以更高的準確性診斷癌症。 製藥商正在開發更有效且與患者身體相容的藥物。

胃癌盛行率不斷上升

胃癌的盛行率正在迅速增加。 這種疾病盛行率上升的可能原因有很多，包括生活方式和飲食習慣的改變以及人口因素。 此類胃癌在分子層面上與其他類型不同，因此需要採用不同的標靶治療方法。 隨著胃癌在各年齡層尤其是老年人中的盛行率持續上升，對有效治療和創新治療方法的需求也在增加。 應對這項挑戰需要透過開發先進的診斷方法來重點關注早期發現，提高人們對該疾病的認識以及定期健康檢查的重要性。

技術進步

診斷技術的進步也對市場產生重大影響。 這些進展將徹底改變胃癌的識別、治療和監測，最終有利於患者的預後。 現代診斷技術，例如具有高清影像的內視鏡檢查，可以準確地觀察胃黏膜，從而可以在早期發現異常和病變。 透過先進的影像方式，如磁振造影 (MRI) 和正子斷層掃描 (PET)，可以對疾病進展進行準確的分期和監測。 分子生物標記分析透過檢測與胃癌相關的特定遺傳和分子變化，正在徹底改變診斷領域。 此方法可用於風險評估、早期檢測和治療效果預測。

機器學習和人工智慧的整合也提高了診斷準確性。 可以使用人工智慧演算法分析大型資料集，以找到指向胃癌的小模式和特徵。 這可以實現更快、更準確的診斷。 世界向遠距醫療和數位醫療解決方案的轉變使得獲得專家建議、第二意見和遠距諮詢變得更加容易，特別是在衛生基礎設施薄弱的地區。 這些進展將使胃癌的早期檢測成為可能，為醫生提供做出明智的治療決策所需的信息，並支持制定量身定制的治療方法。

本報告調查了全球 HER2+ 胃癌市場，提供了市場定義和概述、市場規模趨勢和預測、各個細分市場和地區的詳細分析、行業結構以及影響市場成長的因素分析。、監管框架、案例主要公司的研究、競爭格局和概況。

目錄

第1章研究方法

第 2 章專案範圍與定義

第 3 章執行摘要

第4章全球HER2+胃癌市場展望

  • 市場規模/預測
  • 依治療類型
    • 化療
    • 免疫治療
    • 放射治療
    • 標靶治療
    • 其他
  • 依階段
    • 第一階段
    • 第二階段
    • 第三階段
    • 第四階段
  • 按最終用戶
    • 醫院
    • 專科診所
    • 門診手術中心
    • 其他
  • 按地區
    • 北美
    • 歐洲
    • 南美洲
    • 亞太地區
    • 中東/非洲
  • 各公司的市佔率

第5章全球 HER2+ 胃癌市場展望：按地區

  • 北美
  • 歐洲
  • 南美洲
  • 亞太地區
  • 中東/非洲

第 6 章市場映射

  • 依治療類型
  • 依階段
  • 按最終用戶
  • 按地區

第7章宏觀環境與產業結構

  • 需求與供給分析
  • 匯入/匯出分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市場動態

  • 生長促進因素
  • 抑制生長的因素（問題/抑制因素）

第 9 章監理架構與創新

  • 臨床試驗
  • 專利情況
  • 監理機關的核准
  • 創新/新興技術

第10章主要公司狀況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 位市場領導者的市場收入分析
  • 併購/合資企業（如果適用）
  • SWOT 分析（主要公司）
  • 專利分析（如果適用）

第11章價格分析

第 12 章案例研究

第13章主要公司展望

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 位市場領導者的市場收入分析（%，2023 年）
  • 併購/合資企業（如果適用）
  • SWOT 分析（針對 5 位市場參與者）
  • 專利分析（如果適用）

第11章價格分析

第 12 章案例研究

第13章主要公司展望

  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb
  • Ono Pharmaceutical Co. Ltd
  • Hutchison Medipharma
  • LintonPharm Ltd
  • Shanghai Henlius Biotech Inc
  • Sanofi S A
  • Pfizer Inc.
  • Novartis AG
  • Abott Inc.

第 14 章策略建議

第15章關於我們公司/免責聲明

Product Code: MX11127

Global HER2+ gastric cancer market is projected to witness a CAGR of 3.37% during the forecast period 2024-2031, growing from USD 1304.5 million in 2023 to USD 1700.59 million in 2031. Globally, gastric cancer ranks third in terms of cancer-related deaths and is the sixth most frequent type of cancer. Although there are no symptoms associated with early stomach cancer, some people receive confirmation about the cancer once they are diagnosed. A growth-promoting protein called HER2 is overexpressed on the surface of stomach cancer cells and treatment for these cancers often involves the use of drugs that specifically target the HER2 protein.

The HER2+ gastric cancer market is experiencing growth due to rising numbers of stomach cancer cases. The rise in these cases is seen across all the ages. Technological advancements, increasing investments in R&D, along with governments initiatives are also fueling the market. The prevalence of stomach cancer is increasing at a rapid rate globally, making it almost 5% of all different types of cancer. The market is experiencing technological advancements in terms of solutions that are capable of diagnosing cancer with less time and high accuracy. Pharmaceutical manufacturers are developing drugs that are more effective and compatible with patient's body.

In February 2022, Prime Research Institute and Ono Pharmaceuticals Co., along with Bristol-Myers Squibb, entered a contractual based collaboration to start a large scale, industry sponsored, clinical investigation involving patients with gastric cancer who were undergoing a treatment with Opdivo in combination with chemotherapy. "CyberOncology". It is a data input system developed by PRiMER-R that standardizes, organizes, manages, and integrates real-world data collected from routine cancer clinical practices.

Increasing Prevalence of Gastric Cancer

The prevalence of gastric cancer is rising at a rapid pace. There may be various reasons for the rising prevalence of this disease such as changing lifestyles, dietary habits, and population and demographics. However, what triggers it in the body may be over-expression or over-proliferation of HER2 protein that is present in the body. This form of gastric cancer is different from other types on a molecular level, due to which it is required to be treated differently through targeted therapies. As the prevalence of gastric cancer continues to rise in all age groups, especially the elderly, the demand for effective therapies and innovative treatment approaches also grows. This challenge needs to be addressed by emphasizing more on early detection by developing advanced diagnostic methods, spreading awareness to people about the disease, and communicating the importance of getting regular health checkups. According to a recent study published by ICMR, the number of Indians suffering from cancer is expected to grow to 29.8 million in the year 2025, from 26.7 million in 2021. Accordingly, talking about the burden of cancers in India, seven cancer types account for more than 40% of the total disease burden, whereas gastric cancer itself accounts for 5.2% alone.

Advancements in Technology

Technological advancements made for diagnosis have been playing a major role in influencing the global market for gastric cancer therapy. These developments are revolutionizing the identification, treatment, and monitoring of stomach cancer, which will ultimately benefit patients' prognosis. Modern diagnostic techniques, such as endoscopy with high-definition imaging, enable precise visualization of the stomach lining and detection of anomalies and lesions in their early stages. Accurate staging and disease progression monitoring are made possible by advanced imaging modalities like magnetic resonance imaging (MRI) and positron emission tomography (PET) scans. Molecular biomarker analysis is transforming the field of diagnosis by detecting particular genetic and molecular changes linked to stomach cancer. This method helps with risk assessment, early detection, and treatment response prediction.

Integration of machine learning and artificial intelligence (AI) improves diagnostic precision. Large datasets may be analyzed by Al algorithms, which can then be used to find small patterns and traits that point to stomach cancer. This allows for earlier and more accurate diagnosis. Access to expert advice, second opinions, and remote consultations is becoming easier due to the global shift towards telemedicine and digital health solutions, especially in areas with weak healthcare infrastructure. These developments enable early detection of stomach cancer, provide doctors with the information they need to make well-informed treatment decisions and support the creation of tailored therapeutic methods.

In September 2022, Henlius' HLX22, an anti-human epidermal growth factor receptor-2 (HER2) humanized monoclonal antibody (mAb) injection, underwent a phase 1 clinical trial in patients with advanced solid tumors overexpressing HER2. The study's findings proved that HLX22 is safe and clinically effective.

Immunotherapies are Dominating the Market

Immunotherapy utilizes the body's immune system to recognize and eliminate cancer cells. Treatment options for gastric cancer are limited but immunotherapy has emerged as a clinically advanced alternative. Immune checkpoint inhibitors are a part of immunotherapies that have gained traction over the past few years. Checkpoint proteins like PD-1, PD-L1 and CTLA-4, which are exploited by the cancer cells to evade the immune response, are targeted by these drugs. The immune checkpoint inhibitors block these proteins and hence enable the immune system to build a strong attack against cancer. There have been times when patients who stopped responding to any other therapies have shown great results after going through immunotherapy. It also gives an experience of prolonged survival and a better quality of life. Combining immunotherapy with other therapies like targeted therapy and chemotherapy has proven to be of maximum effectiveness with the potential to stimulate long-lasting immune responses. The dominance of Immunotherapy flags a shift in this market, enabling rapid evolution of the market.

For instance, stage 1 of the worldwide phase III trial enrollment was completed in January 2022 by LintonPharm Co., Ltd., a biopharmaceutical firm based in China that specializes in the development of T cell-engaging bispecific antibodies for cancer immunotherapy. In this experiment, adult patients with advanced gastric cancer and peritonitis were assessed for safety and effectiveness with a bispecific monoclonal antibody called catumaxomab (GCPC).

North America to Dominate Gastric Cancer Market

Countries from North America, such as the United States, Canada, and Mexico, are contributing to market expansion due to the prevalence of gastric cancer, the availability of advanced healthcare infrastructure, the availability of healthcare professionals, and high healthcare expenditure. There is a significant burden of gastric cancer in North America, with millions of new cases being reported each year. The availability of advanced technologies, drugs, and diagnostics that give results faster and with more precision, modern infrastructure, vaccinations, and all the possible treatment options have created a very favorable environment for the development and expansion of this market in North America. Moreover, with the presence of many leading biopharmaceuticals in the region that have a strong and established pipeline of HER2+ gastric cancer treatments, the region is prone to market expansion with continued investment from the government and pharmaceutical companies.

According to statistics published in 2024 by the American Cancer Society for stomach cancer in the United States, there are about 26,890 new cases of gastric cancer, out of which 16,160 were recorded in men and 10,730 in women. There are about 10,880 deaths associated with this type of cancer. Out of which 6490 are men and 4390 are women. Stomach cancer accounts for about 1.5% of all new cancers diagnosed in the US, each year.

Future Market Scenario (2024 - 2031F)

The market for HER2+ gastric cancer is anticipated to further rise as people are becoming aware of the molecular subtypes of cancer. Future developments in this market are expected to be influenced by improvements in diagnostics and newly available treatment options, specifically combination therapy. Industry players must continue to collaborate and comply with changing regulatory standards to improve patient outcomes. Since this market has the potential to revolutionize the way illness is treated, if research and development efforts are sustainable, it can provide patients with a better quality of life. Partnerships and collaborations among pharmaceutical companies, healthcare providers, and patient advocacy groups are critical to meet the changing demands of patients with gastric cancer.

For example, in April 2022, BDR Pharmaceuticals introduced a drug called Furmecil, which is an oral generic medicine developed to treat patients with advanced gastric cancer. It is known to be the combination of three drugs - Tegafur, Gimeracil, and Oteracil. This combination has shown to be highly effective and safe as suggested by the BDR Pharmaceuticals itself.

Key Players Landscape and Outlook

There are several key players in the global HER2+ gastric cancer market. Currently, many competitors control most of the market. Among the businesses that are currently governing the market shares are AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd, Hutchison Medipharma, LintonPharm Ltd, Shanghai Henlius Biotech Inc, Sanofi S A, Pfizer Inc., Novartis AG, Abott Inc., etc. These companies are leading the market share due to their continuous efforts toward R&D, technological advancements, and drug development that is effective and reliable.

In November 2023, Alphamab Oncology and CSPC Pharmaceutical Group Co. Ltd jointly stated that a breakthrough therapy designation was granted to a HER2 specific antibody (KN026) combined with chemotherapy for treating gastric cancer and gastroesophageal junction cancer.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global HER2+ Gastric Cancer Market Outlook, 2017-2031F

  • 4.1.Market Size & Forecast
    • 4.1.1.By Value
    • 4.1.2.By Volume
  • 4.2.By Therapy Type
    • 4.2.1.Chemotherapy
    • 4.2.2.Immunotherapy
    • 4.2.3.Radiation Therapy
    • 4.2.4.Targeted Therapy
    • 4.2.5.Others
  • 4.3.By Stage
    • 4.3.1.Stage I
    • 4.3.2.Stage II
    • 4.3.3.Stage III
    • 4.3.4.Stage IV
  • 4.4.By End-user
    • 4.4.1.Hospitals
    • 4.4.2.Specialty Clinics
    • 4.4.3.Ambulatory Surgical Center
    • 4.4.4.Others
  • 4.5.By Region
    • 4.5.1.North America
    • 4.5.2.Europe
    • 4.5.3.Asia-Pacific
    • 4.5.4.South End-user America
    • 4.5.5.Middle East and Africa
  • 4.6.By Company Market Share (%), 2023

5.Global HER2+ Gastric Cancer Market Outlook, By Region, 2017-2031F

  • 5.1.North America*
    • 5.1.1.Market Size & Forecast
      • 5.1.1.1.By Value
      • 5.1.1.2.By Volume
    • 5.1.2.By Therapy Type
      • 5.1.2.1.Chemotherapy
      • 5.1.2.2.Immunotherapy
      • 5.1.2.3.Radiation Therapy
      • 5.1.2.4.Targeted Therapy
      • 5.1.2.5.Others
    • 5.1.3.By Stage
      • 5.1.3.1.Stage I
      • 5.1.3.2.Stage II
      • 5.1.3.3.Stage III
      • 5.1.3.4.Stage IV
    • 5.1.4.By End-user
      • 5.1.4.1.Hospitals
      • 5.1.4.2.Specialty Clinics
      • 5.1.4.3.Ambulatory Surgical Center
      • 5.1.4.4.Others
    • 5.1.5.United States*
      • 5.1.5.1.Market Size & Forecast
      • 5.1.5.1.1.By Value
      • 5.1.5.1.2.By Volume
      • 5.1.5.2.By Therapy Type
      • 5.1.5.2.1.Chemotherapy
      • 5.1.5.2.2.Immunotherapy
      • 5.1.5.2.3.Radiation Therapy
      • 5.1.5.2.4.Targeted Therapy
      • 5.1.5.2.5.Others
      • 5.1.5.3.By Stage
      • 5.1.5.3.1.Stage I
      • 5.1.5.3.2.Stage II
      • 5.1.5.3.3.Stage III
      • 5.1.5.3.4.Stage IV
      • 5.1.5.4.By End-user
      • 5.1.5.4.1.Hospitals
      • 5.1.5.4.2.Specialty Clinics
      • 5.1.5.4.3.Ambulatory Surgical Center
      • 5.1.5.4.4.Others
    • 5.1.6.Canada
    • 5.1.7.Mexico

All segments will be provided for all regions and countries covered

  • 5.2.Europe
    • 5.2.1.Germany
    • 5.2.2.France
    • 5.2.3.Italy
    • 5.2.4.United Kingdom
    • 5.2.5.Russia
    • 5.2.6.Netherlands
    • 5.2.7.Spain
    • 5.2.8.Turkey
    • 5.2.9.Poland
  • 5.3.Asia-Pacific
    • 5.3.1.India
    • 5.3.2.China
    • 5.3.3.Japan
    • 5.3.4.Australia
    • 5.3.5.Vietnam
    • 5.3.6.South Korea
    • 5.3.7.Indonesia
    • 5.3.8.Philippines
  • 5.4.South America
    • 5.4.1.Brazil
    • 5.4.2.Argentina
  • 5.5.Middle East & Africa
    • 5.5.1.Saudi Arabia
    • 5.5.2.UAE
    • 5.5.3.South Africa

6.Market Mapping, 2023

  • 6.1.By Therapy Type
  • 6.2.By Stage
  • 6.3.By End-user
  • 6.4.By Region

7.Macro Environment and Industry Structure

  • 7.1.Demand Supply Analysis
  • 7.2.Import Export Analysis
  • 7.3.Value Chain Analysis
  • 7.4.PESTEL Analysis
    • 7.4.1.Political Factors
    • 7.4.2.Economic System
    • 7.4.3.Social Implications
    • 7.4.4.Technological Advancements
    • 7.4.5.Environmental Impacts
    • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5.Porter's Five Forces Analysis
    • 7.5.1.Supplier Power
    • 7.5.2.Buyer Power
    • 7.5.3.Substitution Threat
    • 7.5.4.Threat from New Entrant
    • 7.5.5.Competitive Rivalry

8.Market Dynamics

  • 8.1.Growth Drivers
  • 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

  • 9.1.Clinical Trials
  • 9.2.Patent Landscape
  • 9.3.Regulatory Approvals
  • 9.4.Innovations/Emerging Technologies

10.Key Players Landscape

  • 10.1.Competition Matrix of Top Five Market Leaders
  • 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4.SWOT Analysis (For Five Market Players)
  • 10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

  • 13.1.AstraZeneca PLC
    • 13.1.1.Company Details
    • 13.1.2.Key Management Personnel
    • 13.1.3.Products & Services
    • 13.1.4.Financials (As reported)
    • 13.1.5.Key Market Focus & Geographical Presence
    • 13.1.6.Recent Developments
  • 13.2.Bayer AG
  • 13.3.Bristol-Myers Squibb
  • 13.4.Ono Pharmaceutical Co. Ltd
  • 13.5.Hutchison Medipharma
  • 13.6.LintonPharm Ltd
  • 13.7.Shanghai Henlius Biotech Inc
  • 13.8.Sanofi S A
  • 13.9.Pfizer Inc.
  • 13.10.Novartis AG
  • 13.11.Abott Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1.Global HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 2.Global HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 3.Global HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 4.Global HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 5.Global HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 6.Global HER2+ Gastric Cancer Market Share (%), By Region, 2017-2031F
  • Figure 7.North America HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 8.North America HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 9.North America HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 10.North America HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 11.North America HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 12.North America HER2+ Gastric Cancer Market Share (%), By Country, 2017-2031F
  • Figure 13.United States HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 14.United States HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 15.United States HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 16.United States HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 17.United States HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 18.Canada HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 19.Canada HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 20.Canada HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 21.Canada HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 22.Canada HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 23.Mexico HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 24.Mexico HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 25.Mexico HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 26.Mexico HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 27.Mexico HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 28.Europe HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 29.Europe HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 30.Europe HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 31.Europe HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 32.Europe HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 33.Europe HER2+ Gastric Cancer Market Share (%), By Country, 2017-2031F
  • Figure 34.Germany HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 35.Germany HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 36.Germany HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 37.Germany HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 38.Germany HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 39.France HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 40.France HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 41.France HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 42.France HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 43.France HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 44.Italy HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 45.Italy HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 46.Italy HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 47.Italy HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 48.Italy HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 49.United Kingdom HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 50.United Kingdom HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 51.United Kingdom HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 52.United Kingdom HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 53.United Kingdom HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 54.Russia HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 55.Russia HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 56.Russia HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 57.Russia HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 58.Russia HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 59.Netherlands HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 60.Netherlands HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 61.Netherlands HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 62.Netherlands HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 63.Netherlands HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 64.Spain HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 65.Spain HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 66.Spain HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 67.Spain HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 68.Spain HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 69.Turkey HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 70.Turkey HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 71.Turkey HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 72.Turkey HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 73.Turkey HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 74.Poland HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 75.Poland HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 76.Poland HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 77.Poland HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 78.Poland HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 79.South America HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 80.South America HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 81.South America HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 82.South America HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 83.South America HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 84.South America HER2+ Gastric Cancer Market Share (%), By Country, 2017-2031F
  • Figure 85.Brazil HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 86.Brazil HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 87.Brazil HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 88.Brazil HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 89.Brazil HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 90.Argentina HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 91.Argentina HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 92.Argentina HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 93.Argentina HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 94.Argentina HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 95.Asia-Pacific HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 96.Asia-Pacific HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 97.Asia-Pacific HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 98.Asia-Pacific HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 99.Asia-Pacific HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 100.Asia-Pacific HER2+ Gastric Cancer Market Share (%), By Country, 2017-2031F
  • Figure 101.India HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 102.India HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 103.India HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 104.India HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 105.India HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 106.China HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 107.China HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 108.China HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 109.China HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 110.China HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 111.Japan HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 112.Japan HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 113.Japan HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 114.Japan HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 115.Japan HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 116.Australia HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 117.Australia HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 118.Australia HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 119.Australia HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 120.Australia HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 121.Vietnam HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 122.Vietnam HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 123.Vietnam HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 124.Vietnam HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 125.Vietnam HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 126.South Korea HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 127.South Korea HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 128.South Korea HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 129.South Korea HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 130.South Korea HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 131.Indonesia HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 132.Indonesia HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 133.Indonesia HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 134.Indonesia HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 135.Indonesia HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 136.Philippines HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 137.Philippines HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 138.Philippines HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 139.Philippines HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 140.Philippines HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 141.Middle East & Africa HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 142.Middle East & Africa HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 143.Middle East & Africa HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 144.Middle East & Africa HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 145.Middle East & Africa HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 146.Middle East & Africa HER2+ Gastric Cancer Market Share (%), By Country, 2017-2031F
  • Figure 147.Saudi Arabia HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 148.Saudi Arabia HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 149.Saudi Arabia HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 150.Saudi Arabia HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 151.Saudi Arabia HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 152.UAE HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 153.UAE HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 154.UAE HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 155.UAE HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 156.UAE HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 157.South Africa HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 158.South Africa HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 159.South Africa HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 160.South Africa HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 161.South Africa HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 162.By Therapy Type Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 163.By Stage Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 164.By End-user Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 165.By Region Map-Market Size (USD Million) & Growth Rate (%), 2023